Sangamo Therapeutics
SGMO
SGMO
130 hedge funds and large institutions have $47.7M invested in Sangamo Therapeutics in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 23 closing their positions.
Holders
130
Holders Change
-4
Holders Change %
-2.99%
% of All Funds
1.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
42
Reduced
43
Closed
23
Calls
$45K
Puts
$72K
Net Calls
-$27K
Net Calls Change
-$37K
Top Buyers
| 1 |
1
D.E. Shaw & Co
New York
|
$2.54M |
| 2 |
2
Acadian Asset Management
Boston,
Massachusetts
|
$2.58M |
| 3 |
3
Two Sigma Investments
New York
|
$1.18M |
| 4 |
4
Two Sigma Advisers
New York
|
$1.13M |
| 5 |
5
Hudson Bay Capital Management
Stamford,
Connecticut
|
$1.36M |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
WT
151
Whittier Trust
South Pasadena,
California
| – | – | -381 | Closed |
|
152
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | – | -84 | Closed |
|
153
Man Group
London,
United Kingdom
| – | – | – | – |
|
|
CFGS
154
Concourse Financial Group Securities
Birmingham,
Alabama
| – | – | – | – |
|
|
BFEC
155
Benjamin F. Edwards & Company
St. Louis,
Missouri
| $0 | 850 | – | – |
|